Isorhamnetin alleviates esophageal mucosal injury in a chronic model of reflux esophagitis.

In conclusion, isorhamnetin attenuated esophageal mucosal injury in rats with chronic RE, possibly by suppressing formation of cytokines and infiltration of inflammatory cells, inhibiting p38 and NFκB pathways, and enhancing HO-1 activity. PMID: 31586635 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/31586635?dopt=Abstract

Source: European Journal of Pharmacology - October 2, 2019 Category: Drugs & Pharmacology Authors: Liu G, Jiang C, Li D, Yao L, Lin Y, Guo B, Qiu J, Wang W, Wang W Tags: Eur J Pharmacol Source Type: research